Enzon Pharmaceuticals, Inc. (ENZN)
| Market Cap | 23.12M |
| Revenue (ttm) | 67,000 |
| Net Income (ttm) | -1.15M |
| Shares Out | 44.22M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | $0.12 |
| Dividend Yield | 38.52% |
| Trading Day | January 19 |
| Last Price | $0.3115 |
| Previous Close | $0.3000 |
| Change ($) | 0.0120 |
| Change (%) | 3.83% |
| Day's Open | 0.3100 |
| Day's Range | 0.2902 - 0.3300 |
| Day's Volume | 50,777 |
| 52-Week Range | 0.08 - 0.36 |
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as...
Looking to Next Step – Acquisition Opportunities Looking to Next Step – Acquisition Opportunities
CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its ...
CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual...
CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a ...
CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax be...
ENZN trades at all time highs, adjusted for dividends, and double the "base case" of the liquidation value.
Trading for less than its liquid book value.
About ENZN
Enzon Pharmaceuticals, Inc is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet. Its headquarters is now in Piscataway, New Jersey. The company is a publicly traded company on NASDAQ under the symbol "ENZN". It's also doing marketing works in Asia areas such as China. In 2012, the company orally presented in Nanjing, China about the symposium of its drug delivery systems, which help improve therapeutic molecules' pharmaceutical properties. (source: Wikipedia)
| Industry Biotechnology | IPO Date Feb 15, 1984 |
| CEO Andrew Rackear | Country United States |
| Stock Exchange OTCMKTS | Ticker Symbol ENZN |